ãã€ãªãã¯ãããžãŒäŒæ¥ã§ãã Aldeyra Therapeutics, Inc. ã¯ãå
ç«ä»åšæ§çŒçŸæ£ããã³å
šèº«çŸæ£ã®æ²»çè¬ã®éçºãšåååãè¡ã£ãŠããŸããå瀟ã®äž»å補ååè£ã¯ããã©ã€ã¢ã€çŸæ£ããã³ã¢ã¬ã«ã®ãŒæ§çµèçã®æ²»çè¬ãšããŠç¬¬ III çžèšåºè©Šéšãè¡ãããŠããç¹çŒè¬ã® reproxalap ã§ãããŸãã墿®æ§ç¡åäœç¶²èçã®äºé²è¬ãšããŠç¬¬ III çžèšåºè©Šéšãåçºæ§ç¡åäœç¶²èãªã³ãè
«ã®æ²»çè¬ãšããŠç¬¬ II çžèšåºè©Šéšãè¡ãããŠãããžãããèé
žéå
é
µçŽ é»å®³å€ ADX-2191 ãéçºããŠããŸããå瀟ã®ããŒããã©ãªãªã«ã¯ããªã³ã墿®æ§çŸæ£ããã³ COVID-19 ã®æ²»çè¬ãšããŠäœ¿çšãããå°ååç±ã·ã§ãã¯ã¿ã³ãã¯è³ª 90 (Hsp90) é»å®³å€ ADX-1612 ãå«ãŸããŠããŸããèªå·±å
ç«çŸæ£ãã¢ã¬ã«ã®ãŒãCOVID-19ã®æ²»çè¬ADX-629ããç¶²èçŸæ£ã®æ²»çè¬ADX-103ãªã©ãççèªçºæ§ïŒRASPïŒã¹ã«ãã³ãžã£ãŒã§ããåå¿æ§ã¢ã«ãããçš®ãç ç©¶ããŠããŸããå瀟ã¯ä»¥åã¯Aldexa Therapeutics, Inc.ãšããŠç¥ãããŠããŸãããã2014幎3æã«Aldeyra Therapeutics, Inc.ã«ç€Ÿåã倿ŽããŸãããAldeyra Therapeutics, Inc.ã¯2004幎ã«èšç«ãããããµãã¥ãŒã»ããå·ã¬ãã·ã³ãã³ã«æ¬ç€Ÿã眮ããŠããŸãã